<?xml version="1.0"?>
<template xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="openEHR/v1/Template">
  <id>61395ba4-329c-4924-bc89-9b199e66884a</id>
  <name>Diabetes Checkpoint Inhibitor Related Toxicity Medications Adult</name>
  <description>
    <lifecycle_state>Initial</lifecycle_state>
    <details>
      <purpose/>
      <use/>
      <misuse/>
    </details>
    <other_details>
      <item>
        <key>MetaDataSet:Sample Set </key>
        <value>Template metadata sample set </value>
      </item>
      <item>
        <key>Acknowledgements</key>
        <value/>
      </item>
      <item>
        <key>Business Process Level</key>
        <value/>
      </item>
      <item>
        <key>Care setting</key>
        <value/>
      </item>
      <item>
        <key>Client group</key>
        <value/>
      </item>
      <item>
        <key>Clinical Record Element</key>
        <value/>
      </item>
      <item>
        <key>Copyright</key>
        <value/>
      </item>
      <item>
        <key>Issues</key>
        <value/>
      </item>
      <item>
        <key>Owner</key>
        <value/>
      </item>
      <item>
        <key>Sign off</key>
        <value/>
      </item>
      <item>
        <key>Speciality</key>
        <value/>
      </item>
      <item>
        <key>User roles</key>
        <value/>
      </item>
    </other_details>
  </description>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.clinical_guidance.v1]">
    <items>
      <item>
        <key>CKT.Clinical Guidance</key>
        <value>&lt;table border=&quot;1&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; style=&quot;vertical-align:top&quot;&gt;&lt;p&gt;Diabetes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; style=&quot;vertical-align:top&quot;&gt;&lt;p&gt;&lt;em&gt;Definition:&lt;/em&gt; T2DM is a combination of insulin resistance and insufficiency that may require oral or insulin therapy. It may be new onset or exacerbated during therapy for nonimmunologic reasons, such as corticosteroid exposure.&lt;/p&gt;&lt;p&gt;Autoimmune T1DM results from islet cell destruction and is often acute onset, with ketosis and an insulin requirement&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; style=&quot;vertical-align:top&quot;&gt;&lt;p&gt;Diagnostic work-up&lt;/p&gt;&lt;p&gt;-&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Monitor patients for hyperglycemia or other signs and symptoms of new or worsening DM, including measuring glucose at baseline and with each treatment cycle during induction for 12 weeks, then every 3-6 weeks thereafter. To guide the work-up in new-onset hyperglycemia, clinicians should consider a patient’s medical background, exposure history, and risk factors for each subtype of DM.&lt;/p&gt;&lt;p&gt;-&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Laboratory evaluation in suspected T1DM should include testing for ketosis in urine and an assessment of the anion gap on a metabolic panel. Anti-glutamic acid decarboxylase, anti-islet cell, or anti-insulin antibodies are highly specific for autoimmune diabetes. Insulin and C-peptide levels can also assist in the diagnosis&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style=&quot;vertical-align:top&quot;&gt;&lt;p&gt;Grading&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align:top&quot;&gt;&lt;p&gt;Management&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style=&quot;vertical-align:top&quot;&gt;&lt;p&gt;G1: Asymptomatic or mild symptoms; fasting glucose value greater than ULN (160 mg/dL); fasting glucose value greater than ULN (8.9 mmol/L); no evidence of ketosis or laboratory evidence of T1DM&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align:top&quot;&gt;&lt;p&gt;Can continue ICPi with close clinical follow-up and laboratory evaluation&lt;/p&gt;&lt;p&gt;-&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; May initiate oral therapy for those with new-onset T2DM&lt;/p&gt;&lt;p&gt;-&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Screen for T1DM if appropriate, for example, acute onset with prior normal values or clinical concern for ketosis&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style=&quot;vertical-align:top&quot;&gt;&lt;p&gt;G2: Moderate symptoms, able to perform ADL, fasting glucose value greater than 160-250 mg/dL; fasting glucose value greater than 8.9-13.9 mmol/L, ketosis or evidence of T1DM at any glucose level&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align:top&quot;&gt;&lt;p&gt;May hold ICPi until glucose control is obtained&lt;/p&gt;&lt;p&gt;-&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Titrate oral therapy or add insulin for worsening control in T2DM&lt;/p&gt;&lt;p&gt;-&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Should administer insulin for T1DM (or as default therapy if there is confusion about type)&lt;/p&gt;&lt;p&gt;-&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Urgent endocrine consultation for any patient with T1DM; in the absence of endocrinology, internal medicine may suffice&lt;/p&gt;&lt;p&gt;-&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Consider admission for T1DM if early outpatient evaluation is not available or sign of ketoacidosis are present&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style=&quot;vertical-align:top&quot;&gt;&lt;p&gt;G3-4: Severe symptoms, medically significant or life-threatening consequences, unable to perform ADL&lt;/p&gt;&lt;p&gt;G3: Greater than 250-500 mg/dL (greater than 13.9-27.8 mmol/L)&lt;/p&gt;&lt;p&gt;G4: Greater than 500 mg/dL (greater than 27.8 mmol/L)&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align:top&quot;&gt;&lt;p&gt;Hold ICPi until glucose control is obtained on therapy with reduction of toxicity to G1 or less&lt;/p&gt;&lt;p&gt;-&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Urgent endocrine consultation for all patients&lt;/p&gt;&lt;p&gt;-&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Initiate insulin therapy for all patients&lt;/p&gt;&lt;p&gt;-&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Admit for inpatient management: Concerns for developing DKA&lt;/p&gt;&lt;p&gt;-&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Symptomatic patients regardless of diabetes type, New-onset T1DM unable to see endocrinology&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; style=&quot;vertical-align:top&quot;&gt;&lt;p&gt;Additional considerations:&lt;/p&gt;&lt;p&gt;-&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Insulin therapy can be used as the default in any case with hyperglycemia&lt;/p&gt;&lt;p&gt;-&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Long-acting therapy alone is not usually sufficient for T1DM, where half of daily requirements are usually given in divided doses as prandial coverage and half as long acting&lt;/p&gt;&lt;p&gt;-&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Insulin doses will be lower in T1DM because of preserved sensitivity (total daily requirement can be estimated at 0.3-0.4 units/kg/day)&lt;/p&gt;&lt;p&gt;-&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; In T2DM, sliding-scale coverage with meals over a few days provides data to estimate a patient’s daily requirements and can be used to more rapidly titrate basal needs&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; style=&quot;vertical-align:top&quot;&gt;&lt;p&gt;All recommendations are expert consensus based, with benefits outweighing harms, and strength of recommendations are moderate&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</value>
      </item>
    </items>
  </annotations>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]"><items><item><key>Technical.ﻩ Technical Traceability</key><value>{~AHSID~61395ba4-329c-4924-bc89-9b199e66884a~NAME~Diabetes Checkpoint Inhibitor Related Toxicity Medications Adult}</value></item></items></annotations><definition xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" name="Diabetes Toxicity Medications">
    <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1" concept_name="Clinical Guidance" max="1" path="/items" name="Clinical Decision Support"/>
  </definition>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-SECTION.adhoc.v1">
    <digest id="MD5-CAM-1.0.1">8AE70853975A75254E6D39A8DE3652AF</digest>
  </integrity_checks>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1">
    <digest id="MD5-CAM-1.0.1">4B2F0F6CD593E442DA9C30277A3EA9CF</digest>
  </integrity_checks>
</template>